Collegium Pharmaceutical

Yahoo Finance • 2 days ago

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling... Full story

Yahoo Finance • 4 days ago

Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory

We came across a bullish thesis on Collegium Pharmaceutical, Inc. on The Catholic Capitalist’s Substack by Logan Shearer. In this article, we will summarize the bulls’ thesis on COLL. Collegium Pharmaceutical, Inc.'s share was trading at $... Full story

Yahoo Finance • 17 days ago

Zevra Therapeutics rises amid takeover speculation

[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Z... Full story

Yahoo Finance • 2 months ago

Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Record Q2 2025 Earnings and Raises Full-Year Guidance

COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL [https://www.chartmill.com/stock/quote/COLL]) REPORTS STRONG Q2 2025 EARNINGS, BEATS ESTIMATES Collegium Pharmaceutical Inc delivered a solid performance in the second quarter of 2025, surpassing... Full story

Yahoo Finance • 2 months ago

Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook

– Generated Record Quarterly Net Revenue of $188.0 Million,Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Mill... Full story

Yahoo Finance • 3 months ago

Collegium Pharma Launches Up To $150 Mln Buyback Program; Stock Up In Pre-market

(RTTNews) - Collegium Pharmaceutical, Inc. (COLL) on Monday announced that its Board of Directors has authorized a new share repurchase program of up to $150 million in stock through December 31, 2026. In the pre-market trading on the Nas... Full story

Yahoo Finance • 4 months ago

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

PALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it’s estimated that replacing extended-release opioids with abuse-deterrent formulations... Full story

Yahoo Finance • 5 months ago

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025 Panel... Full story

Yahoo Finance • 7 months ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leade... Full story

Yahoo Finance • 7 months ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay... Full story

Yahoo Finance • 7 months ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

– Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7 Million – – Achieved Quarterly and F... Full story

Yahoo Finance • 2 years ago

13 Best Short Squeeze Stocks To Buy Now

In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story

Yahoo Finance • 2 years ago

Collegium Pharmaceutical (NASDAQ:COLL) ascends 8.3% this week, taking five-year gains to 77%

The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. But Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has fallen short of that second goal, with... Full story

Yahoo Finance • 2 years ago

Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld... Full story

Yahoo Finance • 2 years ago

12 Cheap NASDAQ Stocks To Buy

In this piece, we will take a look at the 12 cheap NASDAQ stocks to buy. To skip our overview of one of the world's largest stock exchanges and some recent financial news, read 5 Cheap NASDAQ Stocks To Buy. Stocks markets have been taking... Full story

Yahoo Finance • 2 years ago

Collegium Announces $25 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story

Yahoo Finance • 2 years ago

Collegium Reports Third Quarter 2023 Financial Results

– Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19% Year-over-Year – – Received Exten... Full story

Yahoo Finance • 2 years ago

Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023

STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story

Yahoo Finance • 2 years ago

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story

Yahoo Finance • 2 years ago

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story